Document is current

Any future updates will be listed below

US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection

Crossref DOI link: https://doi.org/10.1007/s40261-017-0492-5

Published Online: 2017-01-19

Published Print: 2017-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark